Review



unprocessed human plasma uhpp  (Innovative Research Inc)


Bioz Verified Symbol Innovative Research Inc is a verified supplier
Bioz Manufacturer Symbol Innovative Research Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Innovative Research Inc unprocessed human plasma uhpp
    Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
    Unprocessed Human Plasma Uhpp, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 96/100, based on 209 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/unprocessed human plasma uhpp/product/Innovative Research Inc
    Average 96 stars, based on 209 article reviews
    unprocessed human plasma uhpp - by Bioz Stars, 2026-06
    96/100 stars

    Images

    1) Product Images from "Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy"

    Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

    Journal: bioRxiv

    doi: 10.64898/2026.04.29.721601

    Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.
    Figure Legend Snippet: Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

    Techniques Used: Isolation, BIA-KA, Western Blot, Concentration Assay, Acid Assay, Size-exclusion Chromatography, Transmission Assay, Electron Microscopy, Clinical Proteomics

    Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.
    Figure Legend Snippet: Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

    Techniques Used: Flow Cytometry, Isolation, Labeling, Imaging, Fluorescence, Size-exclusion Chromatography, Clinical Proteomics



    Similar Products

    unprocessed human plasma uhpp  (Innovative Research Inc)
    96
    Innovative Research Inc unprocessed human plasma uhpp
    Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), <t>UHPp</t> (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual <t>unprocessed</t> human plasma; UHPp, pooled unprocessed human plasma; n=3.
    Unprocessed Human Plasma Uhpp, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/unprocessed human plasma uhpp/product/Innovative Research Inc
    Average 96 stars, based on 1 article reviews
    unprocessed human plasma uhpp - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

    Journal: bioRxiv

    Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

    doi: 10.64898/2026.04.29.721601

    Figure Lengend Snippet: Isolation and characterization of EVs in IVIg and SCIg. (A) EVs were isolated from UHPi (gray), UHPp (green), IVIg (red), and SCIg (blue) by SEC. Fifteen fractions (1 mL) were collected, and protein concentrations were determined by BCA assay. Fractions: 1-4 (void); 5-9 (EV-rich), and 10-15 (protein-rich). (B) Immunoblotting of each fraction with anti-human IgG antibodies. (C-E) NTA profile of pooled, concentrated EV-rich fractions (C), diameter (D), and concentration (particles/mL input volume) (E). (F) Representative TEM image of IVIg EVs showing lipid bilayer. Size bar = 100 nm. P-value: * P ≤ 0.05. BCA, bicinchoninic acid assay; EV, extracellular vesicles; IgG, immunoglobulin; IVIg, intravenous immunoglobulin; NTA, nanoparticle tracking analysis; SCIg, subcutaneous immunoglobulin; SEC, size-exclusion chromatography; TEM, transmission electron microscopy; UHPi, individual unprocessed human plasma; UHPp, pooled unprocessed human plasma; n=3.

    Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

    Techniques: Isolation, BIA-KA, Western Blot, Concentration Assay, Acid Assay, Size-exclusion Chromatography, Transmission Assay, Electron Microscopy, Clinical Proteomics

    Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

    Journal: bioRxiv

    Article Title: Translational Opportunity of Engineered IFNγ-eEVs Through Targeted Inhibition of JAK/STAT1 Signaling, Mimicking IVIg Therapy

    doi: 10.64898/2026.04.29.721601

    Figure Lengend Snippet: Flow cytometry phenotyping of CD63-positive EVs. UHPp, and IVIg EVs isolated using dUC or SEC were labeled with DiD and CD63-PE and analyzed by imaging flow cytometry. (A) Representative images of UHPp and IVIg EVs show morphology, BF, CD63, DiD, and scatter channels. (B) Scatter was used to gate out debris (left, gate R1). Fluorescent dot plots of unlabeled samples show background signal (middle) and labeled samples identified DiD + and CD63 + events (right, gate R2). (C) Summary plots of the frequency of EVs identified by scatter (gate R1, left) or fluorescence (gate R2, right) of UHPp, and IVIg EVs isolated using dUC or SEC. BF, bright field; DiD, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt; dUC, differential ultracentrifugation; EV, extracellular vesicles; IVIg, intravenous immunoglobulin; PE, phycoerythrin; SEC, size-exclusion chromatography; UHPp, pooled unprocessed human plasma. Note: two different lots of UHPp and IVIg were used for these experiments.

    Article Snippet: Pooled unprocessed human plasma (UHPp) was obtained from Innovative Research (Novi, MI).

    Techniques: Flow Cytometry, Isolation, Labeling, Imaging, Fluorescence, Size-exclusion Chromatography, Clinical Proteomics